TF and cancer: While TFs have been considered “undruggable” for decades, emerging or improved approaches targeting the modulation of TF activity or expression levels, TF trafficking, and nucleus positioning, or accelerating TF degradation through proteolysis targeting chimeras have repositioned this unique class of drug targets among the most desired cancer therapeutics1,2.